Immuron Limited, an Australian biopharmaceutical firm headquartered in Carlton and founded in 1994, is dedicated to the research, development, and market introduction of polyclonal antibodies. The company maintains a global presence, conducting operations across Australia, Israel, Canada, the United States, and other international territories. Its business activities are segmented into two core areas: Research and Development, and Hyperimmune Products. Immuron currently offers two main products: Travelan: An over-the-counter medication designed to mitigate the risk of travelers’ diarrhea and minor gastrointestinal discomfort. It also functions as a dietary supplement that supports digestive health and protects the gastrointestinal tract. Protectyn: An immune supplement aimed at fostering healthy digestive function and supporting liver vitality. In its development pipeline, Immuron is advancing several candidates: Travelan (IMM-124E): This version is specifically being developed for the U.S. market to reduce the risk of contracting travelers’ diarrhea. IMM-529: A therapeutic treatment for individuals experiencing recurring Clostridium difficile infections. The company has also established strategic collaborations, including a research agreement with the Naval Medical Research Center focused on developing and clinically evaluating a treatment for Campylobacter and enterotoxigenic Escherichia coli infections. Additionally, Immuron holds a collaborative agreement with the Walter Reed Army Institute of Research to create an oral therapeutic specifically for shigellosis.